Japan’s high-tech healthcare system relies heavily on haematology analysers, which automate blood analysis that translates to faster diagnoses and targeted treatment for a wide range of blood conditions. Against this backdrop, Japan’s haematology analysers market is expected to grow at a compound annual growth rate (CAGR) of around 5 per cent through 2033, forecasts GlobalData.
GlobalData reveals that Japan’s haematology analysers market accounted for around 70 per cent of the Asia-Pacific market in 2023, driven by the availability of advanced technology from some of the prominent companies such as Horiba, Sysmex, Nihon Kohden.
Horiba has recently unveiled correlated rouleaux analysis (CoRA) technology integrated into its three latest analysers. This addition enhances the instruments’ existing functionality with a comprehensive profile for assessing inflammatory diseases.
Shreya Jain, Medical Devices Analyst at GlobalData, states, “The utilisation of haematology analysers has been bolstered by their ability to provide accurate diagnostic information, supporting efficient healthcare delivery. However, the cost and turnaround time limitations with these analysers restrict comprehensive testing due to financial strain on healthcare facilities and operational inefficiencies, delaying diagnoses and treatments.”
Horiba’s patented CoRA technology combines CBC and 5-population white blood cell differentiation with rapid erythrocyte sedimentation rate, into one compact analyser and offers test results from whole blood in 60 seconds. This integration is said to reduce costs per test, decrease turnaround times, and conserve valuable laboratory space.
“By addressing the current limitations and prioritising sustainability, Japan is set to revolutionise haematological diagnostics, ensuring high-quality, accessible healthcare for all. Transformative advancements in future are likely to be driven by the integration of AI, enhanced automation, and the development of portable, point-of-care devices,” concludes Jain.